Large addressable market Target the 50,000 most severe heart failure patients eligible for cardiac assistance, with a total potential market valued at over US$5 billion, signaling strong upsell opportunities for hospitals and cardiac centers investing in advanced support devices.

Strategic clinical collaboration Leverage the team of renowned cardiac surgeons and electro-physiologists to establish credibility with cardiology and surgical departments, accelerating adoption through key opinion leaders and pilot programs.

Innovative technology Position FLOWMAKER as a minimally invasive, wirelessly powered, intraventricular flow accelerator that avoids bypass surgery, appealing to procurement teams seeking cutting-edge, patient-friendly devices with shorter recovery and hospital stays.

Financial readiness With $147M in funding and EU/France regional support, pursue co-investment opportunities, government grants, and strategic partnerships to accelerate regulatory milestones, reimbursements, and large-scale deployments.

Clinical adoption pathway Highlight the 90-minute beating-heart implantation workflow and absence of external driveline to drive hospital adoption, training programs, and volume-based purchasing from major medical device distributors and hospital networks.